A Phase 1, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults.
Latest Information Update: 05 Oct 2023
At a glance
- Drugs V 116 (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 16 Apr 2021 Status changed from active, no longer recruiting to completed.
- 05 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 11 Feb 2021 Status changed from not yet recruiting to recruiting.